HLA-A*0201 | B2M

Produktanfrage

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
LBL-019	LBL-019	Phase 2 Clinical		Neoplasms	Details
BI-1910	BI-1910	Phase 2 Clinical	Bioinvent International Ab	Solid tumours; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung	Details
BITR-2101	BITR-2101; BIR-2101; BITT2101; BITT-2101	Phase 1 Clinical		Infections; Neoplasms; Lymphoma, Non-Hodgkin	Details
NBL-020		Phase 1 Clinical	Shanghai Xinshi Biological Medicine Co Ltd	Solid tumours; Neoplasms	Details
SIM1811-03	SIM1811-03; SIM0235; SIM-235	Phase 1 Clinical	Jiangsu Simcere Pharmaceutical Co Ltd	Solid tumours; Neoplasms; Lymphoma, T-Cell, Cutaneous	Details
HFB-2003(HiFiBiO Therapeutics)	HFB-200301; HFB-2003	Phase 1 Clinical	HiFiBiO Therapeutics	Skin Melanoma; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Mesothelioma; Sarcoma; Testicular Neoplasms; Germinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis	Details

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Recombinant human type II tumor necrosis factor receptor-antibody fusion protein(Hisun Biological)		Approved			Mainland China	Psoriasis; Arthritis, Rheumatoid; Spondylitis, Ankylosing	Hisun Biopharmaceutical Co Ltd	2015-04-09	Spondylitis, Ankylosing; Arthritis, Rheumatoid; Psoriasis	Details